

# Gentian Cystatin C Immunoparticles

according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2020/878 Issue date: 18/12/2021 Revision date: 18/12/2021 Version: 1.0 EN

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

### 1.1. Product identifier

Product form	: Mixture
Product name	: Gentian Cystatin C Immunoparticles
Product code	: 1101
Other means of identification	: Gentian Cystatin C Immunoparticles (product codes 1014A, 1014A-CN, 8014A, 8014A-CN) and available
	as part of kits 1100, 1101, 1101USA, 1103, A52761 and B08179

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

#### Relevant identified uses

Industrial/Professional use spec Use of the substance/mixture For professional use onlyLaboratory chemicalsFor in vitro diagnostic use.

### Uses advised against

No additional information available

### 1.3. Details of the supplier of the safety data sheet

Gentian AS Bjørnåsveien 5 1596 Moss - Norway T +47 993 39 905 info@gentian.no - www.gentian.com

### 1.4. Emergency telephone number

Country	Official advisory body	Address	Emergency number	Comment
Australia NSW Poisons Information Centre		Childrens Hospital Westmead+61 2 9845 3969Hawkesbury Road, Sydney131126		Hours of operation: 24hrs
Canada Centre Antipoison du Québec		Pavillon Jeffery Hale Québec	+1 418 654 2731 1 800 463 5060	24 hrs
Hong Kong	Hong Kong Poison Information Centre	Room 2A, Block K, United Christian Hospital 130 Hip Wo Street, Kwun Tong Kowloon	+852 2772 2211	24hrs
India	CEARCH (Center for Education, Awareness and Research on Chemicals and Health)	Supath II Vadaj, Ashram Road 380013 Ahmedabad	+91 982 404 7400	24hrs
Ireland	National Poisons Information Centre Beaumont Hospital	PO Box 1297 Beaumont Road 9 Dublin	+353 1 809 2566 (Healthcare professionals-24/7) +353 1 809 2166 (public, 8am - 10pm, 7/7)	
Israel	Israel Poison Information Center Rambam Health Care Campus	6 Ha'Aliya Street 31096 Haifa	+972 4 854 1900	
Pakistan	National Poisons Control Centre	Jinnah Postgraduate Medical Centre Rafique Shaheed Road 75510 Karachi	+92 21 9920509/35686535	24hrs
Qatar	Qatar Poison Center	PO Box 26999 Al Gharrafa 26999 Doha	+974 4003 1111	9.00-1.00, every day
Saudi Arabia	Drug and Poison Information Center	Pharmaceutical Care Division King Faisal Specialist Hospital & Research Centre 11211 Riyadh	+966 11 442 7604	7:30-17:00 Sunday to Thursday
Singapore	Drug & Poison Information Centre		+65 6423 9119 Ambulance Service: 995	



# Gentian Cystatin C Immunoparticles

according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2020/878

South Africa	Tygerberg Poison Information Centre	Division of Pharmacology, Departmentt of Medicine Faculty of Health Sciences, Tygerberg Campus, Stellenbosch University 7505 Tygerberg	+27 (0)861 555 777	
Thailand	Ramathibodi Poison Center Faculty of Medicine Ramathibodi Hospital	Mahidol University 10400 Bangkok	1367, Line ID poisrequest (national callers)	
United Arab Emirates	Health Poison and Drug Information Center	Airport Road Abu Dhabi	800 424	7:00-15:00 Sunday- Thursday
United Kingdom	National Poisons Information Service (Newcastle Unit)	Claremont Place Newcastle-upon-Tyne, Newcastle	+44 191 2606182 +44 191 2606180	Hours of operation: 24hrs
USA	National Capital Poison Center	3201 New Mexico Ave Ste 310 Washington DC	+1 202 362 3867 1 800 222 1222	24hrs

### **SECTION 2: Hazards identification**

### 2.1. Classification of the substance or mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP]

Not classified

### Adverse physicochemical, human health and environmental effects

No additional information available

### 2.2. Label elements

Labelling according to Regulation (EC) No. 1272/2008 [CLP]

No labelling applicable

### 2.3. Other hazards

This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII

The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605

## **SECTION 3: Composition/information on ingredients**

### 3.1. Substances

Not applicable

## 3.2. Mixtures

This mixture does not contain any substances to be mentioned according to the criteria of section 3.2 of REACH Annex II

SECTION 4: First aid measures		
4.1. Description of first aid measures		
First-aid measures general	: Never give anything by mouth to an unconscious person. If you feel unwell, seek medical advice (show the label where possible).	
First-aid measures after inhalation	: No particular/specific measures required. Allow affected person to breathe fresh air. Allow the patient to rest.	
First-aid measures after skin contact	: Remove affected clothing and wash all exposed skin area with mild soap and water, followed by warm water rinse.	
First-aid measures after eye contact	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Obtain medical attention if pain, blinking or redness persists.	
First-aid measures after ingestion	: If swallowed, rinse mouth with water (only if the person is conscious). Do NOT induce vomiting. Drink a few glasses of water or milk. Call a poison center or a doctor if you feel unwell.	



## Gentian Cystatin C Immunoparticles

according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2020/878

### 4.2. Most important symptoms and effects, both acute and delayed

- Symptoms/effects after skin contact Symptoms/effects after eye contact Symptoms/effects after ingestion
- : May cause skin irritation.
- er eye contact :
  - : Liquid splashes in the eye may cause irritation.
    - : Ingestion may cause nausea, vomiting and diarrhea.

### 4.3. Indication of any immediate medical attention and special treatment needed

In all cases of doubt, or when symptoms persist, seek medical attention.

#### **SECTION 5: Firefighting measures** 5.1. Extinguishing media Suitable extinguishing media Use extinguishing media appropriate for surrounding fire. Foam. Dry powder. Carbon dioxide. Water spray. Sand. Unsuitable extinguishing media : None to our knowledge. Do not use a heavy water stream. 5.2. Special hazards arising from the substance or mixture Fire hazard : Non flammable. 5.3. Advice for firefighters Firefighting instructions : Use water spray or fog for cooling exposed containers. Exercise caution when fighting any chemical fire. Prevent fire fighting water from entering the environment. Protection during firefighting Do not enter fire area without proper personal protective equipment, including respiratory protection (EN137).

SECTION 6: Accidental release measures			
6.1. Personal precautions, protective equipment and emergency procedures			
General measures	: Concerning personal protective equipment to use, see section 8.		
6.1.1. For non-emergency personnel			
Emergency procedures	: Evacuate unnecessary personnel.		
6.1.2. For emergency responders			
Protective equipment	: Equip cleanup and emergency crew with proper protection.		
Emergency procedures	: Ventilate area.		

#### 6.2. Environmental precautions

Prevent entry to sewers and public waters. Notify authorities if liquid enters sewers or public waters.

### 6.3. Methods and material for containment and cleaning up

For containment Methods for cleaning up	<ul> <li>Collect all waste in suitable and labelled containers and dispose according to local legislation.</li> <li>Take up liquid spill into absorbent material. The contaminated area should be cleaned up immediately</li> </ul>
	with a suitable decontaminant. Store away from other materials.

### 6.4. Reference to other sections

See Section 8. Exposure controls and personal protection.

SECTION 7: Handling and storage			
7.1. Precautions for safe handling			
Precautions for safe handling	: Avoid contact with skin and eyes. Wash hands and other exposed areas with mild soap and water before eating, drinking or smoking and when leaving work. Wear appropriate personal protective equipment - see Section 8. Provide good ventilation in process area to prevent formation of vapour.		
Hygiene measures	: Wash hands thoroughly after use. Wash contaminated clothing before reuse.		
7.2. Conditions for safe storage, including any incompatibilities			
Technical massures	· Comply with applicable regulations		

Technical measures	:	Comply with applicable regulations.
Storage conditions	:	Store in a well-ventilated place. Keep container tightly closed.
Incompatible materials	:	Refer to Section 10 on Incompatible Materials.
Heat and ignition sources	:	Keep away from sources of ignition - No smoking.



# Gentian Cystatin C Immunoparticles

according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2020/878

### 7.3. Specific end use(s)

For in vitro diagnostic use.

## **SECTION 8: Exposure controls/personal protection**

### 8.1. Control parameters

### 8.1.1 National occupational exposure and biological limit values

Gentian Cystatin C Immunoparticles		
Ireland - Occupational Exposure Limits		
Local name Sodium azide (as NaN3)		
OEL TWA [1]	0.1 mg/m <sup>3</sup>	
OEL STEL	0.3 mg/m <sup>3</sup>	
Remark	Sk (Substances which have the capacity to penetrate intact skin when they come in contact with it, and be absorbed into the body), IOELV (Indicative Occupational Exposure Limit Values)	
Regulatory reference         Chemical Agents Code of Practice 2021		
United Kingdom - Occupational Exposure Limits		
Local name	Sodium azide	
WEL TWA (OEL TWA) [1]	0.1 mg/m³ (as NaN3)	
WEL STEL (OEL STEL)	0.3 mg/m³ (as NaN3)	
Remark	Sk (Can be absorbed through the skin. The assigned substances are those for which there are concerns that dermal absorption will lead to systemic toxicity)	
Regulatory reference	EH40/2005 (Fourth edition, 2020). HSE	

### 8.1.2. Recommended monitoring procedures

No additional information available

#### 8.1.3. Air contaminants formed

No additional information available

### 8.1.4. DNEL and PNEC

No additional information available

#### 8.1.5. Control banding

No additional information available

#### 8.2. Exposure controls

#### 8.2.1. Appropriate engineering controls

No additional information available

#### 8.2.2. Personal protection equipment

Personal protective equipment:

Avoid all unnecessary exposure.

### 8.2.2.1. Eye and face protection

Eye protection: Protective goggles. STANDARD EN 166:2001

### 8.2.2.2. Skin protection

#### Skin and body protection:

Wear appropriate clothing to prevent any possibility of skin contact.

### Hand protection:

Wear protective gloves. Nitril. Neoprene. Breakthrough time : 6 (> 480 minutes). Layer thickness : 0,11 mm. STANDARD EN ISO 374-1:2016/A1:2018, EN ISO 374-2:2019, EN ISO 374-4:2019

### 8.2.2.3. Respiratory protection



# Gentian Cystatin C Immunoparticles

according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2020/878

### Respiratory protection:

In case of insufficient ventilation, wear suitable respiratory equipment. Wear appropriate mask. Type A - High-boiling (>65 °C) organic compounds. Standard EN 143:2021

#### 8.2.2.4. Thermal hazards

No additional information available

8.2.3. Environmental exposure controls

### Other information:

Do not eat, drink or smoke during use.

# **SECTION 9: Physical and chemical properties**

### 9.1. Information on basic physical and chemical properties

Physical state		Liquid
Colour	:	White.
Odour	÷	Not available
Odour threshold	÷	Not available
Melting point	÷	Not available
51	÷	Not available
Freezing point	÷	Not available
Boiling point	÷	Not available
Flammability	:	
Explosive limits	:	Not available
Lower explosive limit (LEL)	:	Not available
Upper explosive limit (UEL)	:	Not available
Flash point	:	Not available
Auto-ignition temperature	:	Not available
Decomposition temperature	:	Not available
рН	:	8.6 - 8.9
Viscosity, kinematic	:	Not available
Solubility	:	Not available
Partition coefficient n-octanol/water (Log Kow)	:	Not available
Vapour pressure	:	Not available
Vapour pressure at 50 °C	:	Not available
Density	:	Not available
Relative density	:	Not available
Relative vapour density at 20 °C	:	Not available
Particle size	:	Not applicable
Particle size distribution	:	Not applicable
Particle shape	:	Not applicable
Particle aspect ratio	:	Not applicable
Particle aggregation state	:	Not applicable
Particle agglomeration state	:	Not applicable
Particle specific surface area		Not applicable
Particle dustiness		Not applicable
	•	applicable

### 9.2. Other information

#### 9.2.1. Information with regard to physical hazard classes

No additional information available

#### 9.2.2. Other safety characteristics

No additional information available

## **SECTION 10: Stability and reactivity**

### 10.1. Reactivity

No dangerous reactions known under normal conditions of use.

### 10.2. Chemical stability

Stable under normal conditions of use.

## 10.3. Possibility of hazardous reactions

No dangerous reactions known under normal conditions of use.



## Gentian Cystatin C Immunoparticles

according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2020/878

### 10.4. Conditions to avoid

Direct sunlight. Extremely high or low temperatures.

### 10.5. Incompatible materials

LD50 dermal rabbit

LC50 Inhalation - Rat (Vapours)

Strong acids. Strong bases. Strong oxidizers.

### 10.6. Hazardous decomposition products

May liberate toxic gases. Carbon monoxide. Carbon dioxide.

SECTION 11: Toxicological information		
11.1. Information on hazard classes as define	ed in Regulation (EC) No 1272/2008	
Acute toxicity (oral) Acute toxicity (dermal)	<ul> <li>Not classified (Based on available data, the classification criteria are not met)</li> <li>Not classified (Based on available data, the classification criteria are not met)</li> </ul>	

Acute toxicity (inhalation) :	Not classified (Based on available data, the classification criteria are not met)	
hydrochloric acid (7647-01-0)		
C50 Inhalation - Rat 4726 mg/l/4h		
SODIUM AZIDE (26628-22-8)		
LD50 oral rat	27 mg/kg	

20 mg/kg (ECHA)

0.054 - 0.52 mg/l/4h

Methyl 4-hydroxybenzoate (99-76-3)	
LD50 oral rat	> 5000 mg/kg OECD Guideline 401

sodium hydroxide; caustic soda (1310-73-2)	
LD50 oral	> 500 mg/kg rabbit
Skin corrosion/irritation	: Not classified
	pH: 8.6 – 8.9
Additional information	: Based on available data, the classification criteria are not met : Not classified
Serious eye damage/irritation	: Not classified
Additional information	: Based on available data, the classification criteria are not met
Respiratory or skin sensitisation	: Not classified
Additional information	: Based on available data, the classification criteria are not met
Germ cell mutagenicity	: Not classified
Additional information	: Based on available data, the classification criteria are not met
Carcinogenicity	: Not classified
Additional information	: Based on available data, the classification criteria are not met
Reproductive toxicity	: Not classified
Additional information	: Based on available data, the classification criteria are not met
STOT-single exposure	: Not classified
Additional information	: Based on available data, the classification criteria are not met
hydrochloric acid (7647-01-0)	
STOT-single exposure	May cause respiratory irritation.
STOT-repeated exposure	: Not classified
Additional information	: Based on available data, the classification criteria are not met
SODIUM AZIDE (26628-22-8)	
STOT-repeated exposure	May cause damage to organs through prolonged or repeated exposure.



# Gentian Cystatin C Immunoparticles

Hazardous to the aquatic environment, long-term (chronic)

according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2020/878

Aspiration hazard Additional information	: Not classified : Based on available data, the classification criteria are not met
11.2. Information on other hazards	
11.2.1. Endocrine disrupting properties	
Adverse health effects caused by endocrine disrupting properties	<ul> <li>The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605</li> </ul>
11.2.2 Other information	
Potential adverse human health effects and symptoms	: Based on available data, the classification criteria are not met

SECTION 12: Ecological information		
12.1. Toxicity		
Hazardous to the aquatic environment, short-term (acute)	:	Not classified (Based on available data, the classification criteria are not met)

ydrochloric acid (7647-01-0)		
LC50 - Fish [1]	232 mg/l (96 hours - Gambusia affinis - Mosquito fish)	
EC50 - Crustacea [1]	> 56 mg/l (48 hours - Daphnia magna)	

: Not classified (Based on available data, the classification criteria are not met)

SODIUM AZIDE (26628-22-8)	
LC50 - Fish [1]	2.75 mg/l Oncorhynchus mykiss (Rainbow trout)
EC50 96h - Algae [1]	0.35 mg/l (96 hours - Pseudokirchneriella subcapitata)

Methyl 4-hydroxybenzoate (99-76-3)	
LC50 - Fish [1]	59.5 mg/l Oryzias latipes (Ricefish)
EC50 - Crustacea [1]	11.2 mg/l (48 hours - Daphnia magna)
ErC50 algae	91 mg/l 72 hours - Pseudokirchnerella subcapitata

sodium hydroxide; caustic soda (1310-73-2)		
	LC50 - Fish [1]	45 mg/l (96 hours - Rainbow trout)
	EC50 - Crustacea [1]	30 mg/l Daphnia magna, 48 hours

### 12.2. Persistence and degradability

Gentian Cystatin C Immunoparticles			
Persistence and degradability	Not established.		
2.3. Bioaccumulative potential			
Gentian Cystatin C Immunoparticles			
Bioaccumulative potential	Not established.		
·			
SODIUM AZIDE (26628-22-8)			
Partition coefficient n-octanol/water (Log Pow)	0.3 OECD TG117		
Methyl 4-hydroxybenzoate (99-76-3)			
Bioconcentration factor (BCF REACH)	6.46		
Partition coefficient n-octanol/water (Log Pow)         1.96			



# Gentian Cystatin C Immunoparticles

according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2020/878

sodium hydroxide; caustic soda (1310-73-2)	
Partition coefficient n-octanol/water (Log Pow)	< 0

### 12.4. Mobility in soil

Gentian Cystatin C Immunoparticles	
Ecology - soil	No data available.

### 12.5. Results of PBT and vPvB assessment

Gentian Cystatin C Immunoparticles	
This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII	
This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII	
12.6. Endocrine disrupting properties	

#### 12.6. Endocrine disrupting properties

Adverse effects on the environment caused by endocrine	:	Based on available data, the classification criteria are not met
disrupting properties		

### 12.7. Other adverse effects

Other adverse effects	: None to our knowledge.
Additional information	: Avoid release to the environment.

SECTION 13: Disposal considerations		
13.1. Waste treatment methods		
Waste treatment methods	: Dispose of contents/container in accordance with licensed collector's sorting instructions.	
Product/Packaging disposal recommendations	<ul> <li>Dispose in a safe manner in accordance with local/national regulations. Avoid release to the environment.</li> </ul>	
Additional information	: The given LoW-code is a guiding, and the code depends on how the waste is formed. User must evaluate the choice of correct code.	
Ecology - waste materials	: Avoid release to the environment.	
European List of Waste (LoW) code	<ul> <li>18 01 03* - wastes whose collection and disposal is subject to special requirements in order to prevent infection</li> <li>18 01 06* - chemicals consisting of or containing dangerous substances</li> </ul>	

## **SECTION 14: Transport information**

ADR	IMDG	ΙΑΤΑ	ADN	RID
14.1. UN number or ID numb	er	·		·
Not applicable	Not applicable	Not applicable	Not applicable	Not applicable
14.2. UN proper shipping na	ne			
Not applicable	Not applicable	Not applicable	Not applicable	Not applicable
14.3. Transport hazard class	(es)		,	•
Not applicable	Not applicable	Not applicable	Not applicable	Not applicable
14.4. Packing group				
Not applicable	Not applicable	Not applicable	Not applicable	Not applicable
14.5. Environmental hazards				
Not applicable	Not applicable	Not applicable	Not applicable	Not applicable

### 14.6. Special precautions for user

**Overland transport** Not applicable

## Gentian Cystatin C Immunoparticles

according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2020/878

### Transport by sea

Not applicable Air transport Not applicable Inland waterway transport Not applicable Rail transport Not applicable

### 14.7. Maritime transport in bulk according to IMO instruments

Not applicable

## **SECTION 15: Regulatory information**

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

### 15.1.1. EU-Regulations

Contains no REACH substances with Annex XVII restrictions

Contains no substance on the REACH candidate list

Contains no REACH Annex XIV substances

Contains no substance subject to Regulation (EU) No 649/2012 of the European Parliament and of the Council of 4 July 2012 concerning the export and import of hazardous chemicals.

Contains no substance subject to Regulation (EU) No 2019/1021 of the European Parliament and of the Council of 20 June 2019 on persistent organic pollutants

#### 15.1.2. National regulations

No additional information available

### 15.2. Chemical safety assessment

No chemical safety assessment has been carried out

SECTION 16: Other information			
Data sources	<ul> <li>REGULATION (EC) No 1272/2008 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006.</li> </ul>		
Other information	: None.		

The information in this safety data sheet is based on information from the manufacturer/supplier, present european and national legislation, and presupposes that the product is used within the specified area of application.

